Risk signature-guided adjuvant therapy for specific age and anatomical-stage-based subgroups of ER-positive/HER2-negative BC has been recommended by the Swedish national breast cancer guidelines since 2019, but the clinical implementation has been relatively conservative due to concerns regarding risk for undertreatment [21]. The gene discussed is ERBB2; the disease is breast cancer.